Research Reports

---

 Vectorspace AI science and technology originated in Life Sciences and currently focuses on context-controlled NLP/NLU (Natural Language Processing/Understanding) and feature engineering for hidden relationship detection in data for the purpose of powering advanced approaches in Artificial Intelligence (AI) and Machine Learning (ML). Our platform powers research groups, data vendors, funds and institutions by generating on-demand NLP/NLU correlation matrix datasets. We are particularly interested in how we can engineer machines to trade information with one another or exchange and transact data in a way that minimizes a selected loss function. Our objective is to enable any group analyzing data to save time by testing a hypothesis or running experiments with higher throughput. This can increase the speed of innovation, novel scientific breakthroughs and discoveries.   https://vectorspace.ai/

Coverage Highlight:    Ludlow Research Initiates Updates Opinion on Vectorspace AI (VXV) Based on Demand for Data Sets Involved in Wall Street Trading

Price Target: $0.75 to $1.00+

 Ideanomics, Inc. focuses on monetizing the adoption of commercial electric vehicles, associated energy consumption, and developing financial services and Fintech products. Its Mobile Energy Global division provides financial services and incentives for commercial fleet operators, including group purchasing discounts and battery buy-back programs. This division also offers solutions for the procurement, financing, charging, and energy management needs for fleet operators of commercial electric vehicles. The company's Ideanomics Capital division provides financial services solutions. This division is involved in the areas of capital markets, such as financial products advisory and creation, with specific focus on the application of blockchain and artificial intelligence in financial technology. This division also operates EKAR, an exchange traded fund that tracks the Innovation Labs Next Generation Vehicles Index, which comprises of global stocks that have exposure to the theme of electric and self driving/autonomous vehicles. https://ideanomics.com/

 

Coverage Highlight:   Ludlow Research Places Ideanomics (IDEX) on Watch for Possible Near-term Bottom as Chart Gap Refills

Price Target: NA

Inseego Corp. engages in the design and development of mobile, Internet of Things (IoT), and cloud solutions for large enterprise verticals, service providers, and small and medium-sized businesses worldwide. The company provides wireless 3G, 4G, and 5G hardware products for vertical markets, including private LTE/5G networks, First responders network authority/Firstnet, SD-WAN, telematics, remote monitoring and surveillance, and fixed wireless access and mobile broadband devices. Its products include 4G and 5G fixed wireless routers and gateways, and mobile hotspots, and wireless gateways and routers for IIoT applications

Coverage Highlight:    Ludlow Research Initiates Coverage on INSG Based on Valuation and Coming Investor Demand for 5G Stocks

Price Target: $16.00 to $18.00

 Riot Blockchain (NASDAQ: RIOT) specializes in cryptocurrency mining with a focus on bitcoin. Riot also holds non-controlling investments in blockchain technology companies. Riot is headquartered in Castle Rock, Colorado, and the Company’s primary mining facility is located in Oklahoma City, Oklahoma. For more information, visit www.RiotBlockchain.com  

Coverage Highlight: RIOT is positioned for upside interest as demand for bitcoin grows as an alternative investment to Gold and US Treasuries.
Short-term Target: $4.00 to $5.00

•  Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1. In addition Auris Medical has two Phase 3 programs under development: AM-111 for sudden sensorineural hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.